Please login to the form below

Not currently logged in
Email:
Password:

Boehringer Ingelheim's Dr Susan Anton joins Icon

The CRO also appoints Dr Pui Leung, boosting its early phase and epidemiology and risk management teams

Icon has appointed former Boehringer Ingelheim director Dr Susan Anton to head up its epidemiology and risk management practice.

The move is one of two senior appointments at the contract research organisation (CRO), which also see Dr Pui Leung join at a senior clinical research physician.

Dr Anton has more than 25 years of experience leading international epidemiologic, health economic, and outcomes research, and other market access initiatives.

Most recently she served as director of US medical outcomes research and registries at Boehringer Ingelheim, and prior to that directed health economic, epidemiologic and outcomes research efforts across therapeutic areas at Bristol-Myers Squibb.

Meanwhile, Dr Leung, who will be based at Icon's clinical pharmacology unit in Manchester, UK, has 10 years of experience as a senior phase I clinical research physician in two UK CROs.

Before joining the pharmaceutical industry in 2002, he spent 13 years as a hospital physician in the UK's National Health Service (NHS).

22nd May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

04 A Healthy Ambience
Creating a Lifeline to the New Digital User...
03 Health Services
How Pharma Companies Can Survive the Patent Cliff Through Digital Innovation...
From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...

Infographics